Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
← catalyst calendarNCT07049575 · readout in 111 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
24estimated
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-03 | actual | When the study began enrolling |
| Primary completion | 2026-12-09 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-09 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Intervention
- Drug: Ruxolitinib Cream
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment-emergent Adverse Events (TEAEs)
measured Up to 24 weeks
Number of participants with TEAEs leading to treatment interruption, discontinuation
measured Up to 24 weeks
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed